TY - GEN
T1 - New technology to reduce complications and procedure time in cranial and spinal surgery
AU - Modak, Piyush
AU - Hammond, Willis
AU - Jaffe, Michael
AU - Nadig, Malavika
AU - Russo, Richard
N1 - Funding Information:
Conclusions: We have developed a unique two biopolymer erodible system that forms a hydrogel in situ. The current study demonstrates the ability of the hydrogel to shrink, even when completely immersed in an aqueous medium. An in vivo study demonstrates the rapid hemostasis achieved by the hydrogel in progressively more aggressively bleeding wounds and the formation of a stable clot in all the wound types. These results demonstrate the potential of our technology to be used as a surgical hemostat to address unmet needs for brain and spine surgical applications. References:[1]Gelfoam.Instructions for Use.Pfizer. 2017. [2]Bennett BL.J Spec Oper Med.2014;14(3):40-57. Grant support from NIH NINDS SBIR R44 NS070331
Publisher Copyright:
© 2019 Omnipress - All rights reserved.
PY - 2019
Y1 - 2019
N2 - Statement of Purpose: Commercially available absorbable surgical hemostats swell in use (20-200%) because they absorb fluids and can compress the neighboring tissues leading to complications. This is especially a problem in cranial and spine surgery because the swollen hemostats cause neural compression leading to pain, paresis, and paralysis [1]. Such hemostats are also slow acting and can take up to 10 minutes to achieve hemostasis, and these are often used several times per case. In this study, we present a patented system of two natural polysaccharides that form a hydrogel device in situ without the use of an external crosslinking agent. Even though one of the starting materials in our system, chitosan, has been shown to be hemostatic in in vitro tests, more appropriate testing using in vivo critical defect models demonstrated it to be not hemostatic [2]. We have chemically modified the chitosan to be water-soluble so that it interacts with oxidized dextran via Schiff base formation to form a unique hydrogel structure that: 1) produces hemostasis in a short time, 2) leads to stable clot formation and 3) gently shrinks with time.
AB - Statement of Purpose: Commercially available absorbable surgical hemostats swell in use (20-200%) because they absorb fluids and can compress the neighboring tissues leading to complications. This is especially a problem in cranial and spine surgery because the swollen hemostats cause neural compression leading to pain, paresis, and paralysis [1]. Such hemostats are also slow acting and can take up to 10 minutes to achieve hemostasis, and these are often used several times per case. In this study, we present a patented system of two natural polysaccharides that form a hydrogel device in situ without the use of an external crosslinking agent. Even though one of the starting materials in our system, chitosan, has been shown to be hemostatic in in vitro tests, more appropriate testing using in vivo critical defect models demonstrated it to be not hemostatic [2]. We have chemically modified the chitosan to be water-soluble so that it interacts with oxidized dextran via Schiff base formation to form a unique hydrogel structure that: 1) produces hemostasis in a short time, 2) leads to stable clot formation and 3) gently shrinks with time.
UR - http://www.scopus.com/inward/record.url?scp=85065400698&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85065400698&partnerID=8YFLogxK
M3 - Conference contribution
AN - SCOPUS:85065400698
T3 - Transactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
SP - 740
BT - Society for Biomaterials Annual Meeting and Exposition 2019
PB - Society for Biomaterials
T2 - 42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
Y2 - 3 April 2019 through 6 April 2019
ER -